Arbutus Biopharma Corporation

Rule Changes

Settlement plaintiff; pursuing Pfizer/BioNTech separately

For four years, the question of whether Moderna owed billions for technology at the heart of its COVID-19 vaccine hung over the company. Less than a week before a jury trial was set to begin in Delaware, Moderna agreed to pay up to $2.25 billion to settle patent claims brought by Arbutus Biopharma and Genevant Sciences—accepting a court judgment that it infringed four patents and that those patents are valid. If the full amount is paid, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated Mar 4